Bruce L. Levine

faculty photo
Barbara and Edward Netter Professor in Cancer Gene Therapy
Abramson Cancer Center of the University of Pennsylvania (Member), Abramson Cancer Center of the University of Pennsylvania (Member)
Deputy Director - Technology Innovation and Assessment, Center for Cellular Immunotherapies, University of Pennsylvania Department of Pathology and Laboratory Medicine, Perelman School of Medicine
Founding Director, Clinical Cell and Vaccine Production Facility, University of Pennsylvania Department of Pathology and Laboratory Medicine, Perelman School of Medicine and Abramson Cancer Center
Department: Pathology and Laboratory Medicine

Contact information
Center for Cellular Immunotherapies
Smilow 8-114
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-746-1481
Graduate Group Affiliations
Education:
B.A. (Major-Biology, Minor-History)
The University of Pennsylvania , 1984.
Ph.D. (Immunology and Infectious Diseases)
The Johns Hopkins University, 1992.
Permanent link
 

Description of Research Expertise

Immunology, Cell and Gene Therapy

Description of Other Expertise

Good Manufacturing Practices

Description of Itmat Expertise

Dr. Levine's interests include cell, gene, and biologic therapy clinical trial development, manufacturing, and testing and lymphocyte growth, activation and senescence.

Selected Publications

Cohen Adam D, Garfall Alfred L, Stadtmauer Edward A, Melenhorst J Joseph, Lacey Simon F, Lancaster Eric, Vogl Dan T, Weiss Brendan M, Dengel Karen, Nelson Annemarie, Plesa Gabriela, Chen Fang, Davis Megan M, Hwang Wei-Ting, Young Regina M, Brogdon Jennifer L, Isaacs Randi, Pruteanu-Malinici Iulian, Siegel Don L, Levine Bruce L, June Carl H, Milone Michael C: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of Clinical Investigation 130: 126397, Mar 2019.

Stein Andrew M, Grupp Stephan A, Levine John E, Laetsch Theodore W, Pulsipher Michael A, Boyer Michael W, August Keith J, Levine Bruce L, Tomassian Lori, Shah Sweta, Leung Mimi, Huang Pai-Hsi, Awasthi Rakesh, Mueller Karen Thudium, Wood Patricia A, June Carl H: Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells. CPT: pharmacometrics & systems pharmacology Mar 2019 Notes: ePub ahead of print doi: 10.1002/psp4.12388.

Harrison Richard P, Zylberberg Ezequiel, Ellison Simon, Levine Bruce L: Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy 21(2): 224-233, Feb 2019.

Mueller Karen T, Waldron Edward R, Grupp Stephan A, Levine John E, Laetsch Theodore W, Pulsipher Michael A, Boyer Michael W, August Keith, Hamilton Jason, Awasthi Rakesh, Stein Andrew M, Sickert Denise, Chakraborty Abhijit, Levine Bruce L, June Carl H, Tomassian Lori, Shah Sweta, Leung Mimi, Taran Tetiana, Wood Patricia A, Maude Shannon L: Clinical Pharmacology of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia. Clinical Cancer Research 24(24): 6175, December 2018.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ: Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine 24(10): 1499-1503, October 2018.

Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, Melenhorst JJ, Milone MC: Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells. Cancer Immunol Res. 6(9): 100-1109, September 2018 Notes: doi: 10.1158/2326-6066.CIR-17-0405. [Epub ahead of print]

Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ: Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma. Blood 132(10): 1022-1026, September 2018 Notes: doi: 10.1182/blood-2018-03-837609. [Epub ahead of print]

Fraietta JA1, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, Bushman FD, June CH, Melenhorst JJ: Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558(7709): 307-312, May 2018 Notes: doi:10.1038/s41586-018-0178-z.

Fraietta Joseph A, Lacey Simon F, Orlando Elena J, Pruteanu-Malinici Iulian, Gohil Mercy, Lundh Stefan, Boesteanu Alina C, Wang Yan, O'Connor Roddy S, Hwang Wei-Ting, Pequignot Edward, Ambrose David E, Zhang Changfeng, Wilcox Nicholas, Bedoya Felipe, Dorfmeier Corin, Chen Fang, Tian Lifeng, Parakandi Harit, Gupta Minnal, Young Regina M, Johnson F Brad, Kulikovskaya Irina, Liu Li, Xu Jun, Kassim Sadik H, Davis Megan M, Levine Bruce L, Frey Noelle V, Siegel Donald L, Huang Alexander C, Wherry E John, Bitter Hans, Brogdon Jennifer L, Porter David L, June Carl H, Melenhorst J Joseph: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine 24(5): 563-571, May 2018.

Garfall Alfred L, Stadtmauer Edward A, Hwang Wei-Ting, Lacey Simon F, Melenhorst Jan Joseph, Krevvata Maria, Carroll Martin P, Matsui William H, Wang Qiuju, Dhodapkar Madhav V, Dhodapkar Kavita, Das Rituparna, Vogl Dan T, Weiss Brendan M, Cohen Adam D, Mangan Patricia A, Ayers Emily C, Nunez-Cruz Selene, Kulikovskaya Irina, Davis Megan M, Lamontagne Anne, Dengel Karen, Kerr Naseem Ds, Young Regina M, Siegel Donald L, Levine Bruce L, Milone Michael C, Maus Marcela V, June Carl H: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI insight 3(8): e120505, Apr 2018.

back to top
Last updated: 07/29/2019
The Trustees of the University of Pennsylvania